IMA (ImageneBio) Total Liabilities: $13.36 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMA ImageneBio Inc IMA
10 GF Score
Price $5.59
! 3 Warning Signs
View Full Analysis

What is ImageneBio Total Liabilities?

ImageneBio IMA +0.36% 10 Total Liabilities is $13.36 Mil as of Mar. 2026. GuruFocus rates IMA with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

ImageneBio's Total Liabilities for the quarter that ended in Mar. 2026 was $13.36 Mil.

ImageneBio's quarterly Total Liabilities declined from Sep. 2025 ($21.05 Mil) to Dec. 2025 ($19.84 Mil) and declined from Dec. 2025 ($19.84 Mil) to Mar. 2026 ($13.36 Mil).

ImageneBio's annual Total Liabilities increased from Dec. 2023 ($157.35 Mil) to Dec. 2024 ($176.49 Mil) but then declined from Dec. 2024 ($176.49 Mil) to Dec. 2025 ($19.84 Mil).

ImageneBio Total Liabilities Historical Data

* Premium members only.

The historical data trend for ImageneBio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImageneBio Total Liabilities Chart

ImageneBio Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
157.35 176.49 19.84

ImageneBio Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 176.49 0.00 21.05 19.84 13.36
IMA
10GF Score
ImageneBio Inc IMA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImageneBio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ImageneBio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.234+(0.713+7.89
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.84

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=152.976-133.139
=19.84

ImageneBio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.634+(0.11+5.811
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.36

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=136.682-123.327
=13.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $13.36 Mil mean?
ImageneBio (IMA) has a Total Liabilities of $13.36 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ImageneBio and its competitors.
Is ImageneBio's Total Liabilities too high?
ImageneBio's current Total Liabilities is $13.36 Mil. Overall, ImageneBio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ImageneBio's Total Liabilities compare to HYFT and CING?
ImageneBio's Total Liabilities of $13.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ImageneBio and its competitors. ImageneBio's current Total Liabilities is $13.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImageneBio stock overvalued right now?
ImageneBio (IMA) has a current Total Liabilities of $13.36 Mil. The current Total Liabilities is $13.36 Mil. ImageneBio's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ImageneBio (IMA), the current Total Liabilities is $13.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImageneBio Business Description

Address 12526 High Bluff Drive, Suite 345, San Diego, CA, USA, 92130
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
10GF Score

Get the complete analysis for IMA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.59
Price